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Transcription factor fusion proteins can transform
cells by inducingglobal changesof the transcriptome,
often creating a stateof oncogeneaddiction.Here,we
investigate the role of epigenetic mechanisms in this
process, focusing on Ewing sarcoma cells that are
dependent on theEWS-FLI1 fusionprotein.Weestab-
lished reference epigenome maps comprising DNA
methylation, seven histone marks, open chromatin
states, and RNA levels, and we analyzed the epige-
nome dynamics upon downregulation of the driving
oncogene. Reduced EWS-FLI1 expression led to
widespread epigenetic changes in promoters, en-
hancers, and super-enhancers, and we identified his-
tone H3K27 acetylation as the most strongly affected
mark. Clustering of epigenetic promoter signatures
defined classes of EWS-FLI1-regulated genes that
responded differently to low-dose treatment with
histone deacetylase inhibitors. Furthermore, we ob-
served strong and opposing enrichment patterns
for E2F and AP-1 among EWS-FLI1-correlated and
anticorrelated genes. Our data describe extensive
genome-wide rewiring of epigenetic cell states driven
by an oncogenic fusion protein.INTRODUCTION
Fusion proteins are a common cause of cancer. They often
establish a state of oncogene addiction that makes cancer cells
vulnerable to losing the fusion protein’s biological function (Mac-
conaill and Garraway, 2010). Direct pharmacological inhibition
has been highly effective for certain kinase fusion proteins but
is difficult for transcription factor fusions (Mitelman et al.,
2004). It is therefore important to understand the regulatory1082 Cell Reports 10, 1082–1095, February 24, 2015 ª2015 The Authmechanisms in fusion-protein-driven cancers in order to identify
indirect ways of interfering with these oncogenes.
Here, we focus on epigenetic deregulation as a mechanism by
which an oncogenic fusion protein may rewire cells for malig-
nancy (Chen et al., 2010). We mapped the genome-wide dy-
namics of chromatin marks in a cellular model that is dependent
on the EWS-FLI1 fusion protein. EWS-FLI1 is the most common
initiating event in Ewing sarcoma, a pediatric cancer for which
few therapeutic options exist (Bernstein et al., 2006). This onco-
genic fusion protein originates from a chromosomal transloca-
tion that fuses the activator domain of the RNA binding protein
EWS to the DNA binding domain of the FLI1 transcription factor
(Delattre et al., 1994), and its expression results in upregulation
and downregulation of several hundred target genes (Kovar,
2010). Ewing sarcoma has a lower rate of somatic mutations
than most cancers (Brohl et al., 2014; Crompton et al., 2014;
Huether et al., 2014; Lawrence et al., 2013; Tirode et al., 2014),
suggesting that EWS-FLI1-driven tumors may be particularly
dependent on deregulation of the epigenome.
To study EWS-FLI1-associated epigenetic changes, we per-
formed comprehensive epigenome mapping in Ewing-sar-
coma-derived cells, following the standards of the International
Human Epigenome Consortium (http://ihec-epigenomes.net).
Integrative bioinformatic analysis identified significant asso-
ciations between EWS-FLI1 binding and the chromatin states
of promoters, enhancers, and super-enhancers. We also
compared the epigenomes before and after knockdown of the
EWS-FLI1 fusion protein, allowing us to define clusters of
EWS-FLI1-regulated genes. We validated the relevance of our
gene clustering by measuring the transcriptome response to
epigenome-modulating drugs, and we identified EWS-FLI1-spe-
cific enhancer and super-enhancer signatures that are depen-
dent on EWS-FLI1 expression.
Our results highlight the prevalence, complexity, and dy-
namics of epigenome and transcriptome rewiring orchestrated
by EWS-FLI1, and they provide initial insights into the role of
the epigenome in solid cancer cells that depend on an oncogenic
fusion protein.ors
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Figure 1. Reference Epigenome Maps of Ewing-Sarcoma-Derived Cells at High and Low Levels of EWS-FLI1 Expression
(A) Schematic of an inducible small hairpin RNA (shRNA) system in the Ewing sarcoma cell line A673, which allows for efficient switching between high and low
EWS-FLI1 expression levels. A representative western blot illustrates the efficiency of induced EWS-FLI1 knockdown.
(B) Genome browser screenshot of the reference epigenome maps at a known EWS-FLI1 target gene (BCL11B), shown for high and low levels of EWS-FLI1
expression. The tracks visualize RNA-seq data, ChIP-seq for seven histone marks, DNA methylation levels at single-CpG resolution, and ATAC-seq signal as a
measure of open chromatin. All data are publicly available for interactive exploration and download (http://tomazou2015.computational-epigenetics.org).
(C) Heatmap showing the genome-wide correlation of ChIP-seq and ATAC-seq signals in 1-kb tiling windows. Light colors (white/yellow) correspond to strong
correlation and dark colors (red) correspond to weak or negative correlation.
(D) Scatterplot showing the genome-wide correlation of average DNAmethylation levels (1-kb tiling windows) between biological replicates in the EWS-FLI1-high
state.
(E) Bar charts showing DNAmethylation coverage for combinedWGBS and RRBSdata in CpG islands, promoter regions (1-kb region upstream of TSS), and 1-kb
tiling windows across the genome.
(F) Scatterplot showing the genome-wide correlation of RNA levels (log FPKM [fragments per kilobase of transcript per million mapped reads] values for
assembled transcripts) between biological replicates in the EWS-FLI1-high state.
(G) Bar charts showing RNA-seq coverage at different types of genomic regions and detection levels for known and novel splicing junctions.
See also Figure S1.RESULTS
Reference Epigenome Mapping in a Cellular Model of
EWS-FLI1 Dependence
Epigenome mapping is a powerful method for cataloging func-
tional elements throughout the genome (Bernstein et al., 2012),
and it canprovide insights into the regulatorymechanisms that un-
derlie changes of cell state (Rivera and Ren, 2013). To investigate
the effect of EWS-FLI1 expression on epigenetic cell states, we
mapped the epigenome of an Ewing sarcoma cell line (A673)Cell Rthat has emerged as a standardmodel for systems biology in Ew-
ing sarcoma (http://www.ucd.ie/sbi/asset). This cell line is EWS-
FLI1 dependent and was previously engineered to harbor a doxy-
cycline-inducible small hairpin RNA against EWS-FLI1 (Carrillo
et al., 2007). These cells retain a low level of EWS-FLI1 expression
after knockdown, thus allowing us to compare, in an isogenic
setting, the epigenomes of EWS-FLI1-high and EWS-FLI1-low
cell states without causing extensive cell death (Figure 1A).
We established reference epigenome maps comprising
DNA methylation, seven histone marks (H3K4me3, H3K4me1,eports 10, 1082–1095, February 24, 2015 ª2015 The Authors 1083
H3K27ac, H3K56ac, H3K36me, H3K27me3, and H3K9me3),
open chromatin states, and RNA levels. DNA methylation was
mapped both by whole-genome bisulfite sequencing (WGBS)
and reduced representation bisulfite sequencing (RRBS), his-
tone marks by chromatin immunoprecipitation sequencing
(ChIP-seq), open chromatin states by assay for transposase-
accessible chromatin with high-throughput sequencing (ATAC-
seq), and RNA levels by strand-specific RNA sequencing
(RNA-seq). Each experiment was performed in two biological
replicates each for both the EWS-FLI1-high state (cells in normal
growth conditions) and the EWS-FLI1-low state (53 hr after add-
ing doxycycline to induce knockdown of EWS-FLI1). We also
performed RNA-seq in cells that were treated with each of three
histone deacetylase inhibitors to further dissect the relevance of
histone acetylation in our model. In total, we generated 61 data-
sets and sequenced 2.9 billion reads comprising 221 billion base
pairs (Table S1).
To facilitate data access and reuse by other researchers, we
developed a website for online exploration and data download
(http://tomazou2015.computational-epigenetics.org). Our data-
set can be used to view and investigate the epigenetic changes
in EWS-FLI1-dependent cells one gene at a time (Figure 1B) or to
study patterns of epigenetic and transcriptional deregulation on
a more global level, for example by annotating known and novel
non-coding transcripts and alternative promoters that are EWS-
FLI1 dependent (Figure S1).
Hierarchical clustering of the ChIP-seq and ATAC-seq data
showed high consistency between experiments of the same
type (Figure 1C). We also observed the expected separation
into repressive histone marks (H3K9me3 and H3K27me3), tran-
scription-associated histone marks (H3K36me3), and open-
chromatin-associated marks (H3K4me3, H3K4me1, H3K27ac,
H3K56ac, and ATAC-seq signal). For the DNA methylation
data, which were combined from WGBS and RRBS experi-
ments, we observed high correlation between replicates (Fig-
ure 1D) and broad coverage throughout the genome (Figure 1E).
The correlation among biological replicates was equally high for
the RNA-seq data (Figure 1F), and we were able to identify a
small number of transcripts and splicing isoforms that appear
to be specific to this cell type (Figures 1G and S1). In aggregate,
these observations confirm the high technical data quality of the
reference epigenome maps that we generated.
Significant Association of Gene Expression, EWS-FLI1
Binding, and Open Chromatin
EWS-FLI1 is known to act as a transcriptional activator (Bailly
et al., 1994; Ohno et al., 1993), but it also represses genes—indi-
rectly by activating transcriptional repressor genes and poten-
tially also directly by recruiting repressive protein complexes
(Hahm et al., 1999; Prieur et al., 2004; Sankar et al., 2013). To
investigate the genome-wide association among gene expres-
sion, EWS-FLI1 binding, and chromatin states, we stratified all
genes by their RNA levels (Figure 2A, top) and by the distance
from the transcription start site (TSS) to the nearest EWS-FLI1
binding peaks (Figure 2A, bottom), which were mapped previ-
ously (Bilke et al., 2013), and we plotted average ChIP-seq inten-
sities for each histone mark around the TSS (Figures 2A and S2).
Promoters of highly expressed genes and those bound by1084 Cell Reports 10, 1082–1095, February 24, 2015 ª2015 The AuthEWS-FLI1 had high levels of the open-chromatin-associated
marks H3K4me3, H3K27ac, and H3K56ac. These marks also
showed the characteristic dip at the TSS that is indicative of
nucleosome-free regions (ENCODE Project Consortium, 2012),
and they overlapped with a peak of open chromatin in the
ATAC-seq data. H3K4me1 was similarly enriched in the wider
promoter region but depleted in immediate vicinity of the TSS,
reflecting its mutual exclusivity with H3K4me3. Furthermore,
H3K36me3 levels were high in genic regions directly down-
stream of the TSS of genes that were highly expressed and
bound by EWS-FLI1, whereas the repressive histone marks
H3K9me3 and H3K27me3 were depleted in the promoters of
these genes (Figures 2A and S2). Promoters with distal EWS-
FLI binding (5–40 kb from the TSS) were no more enriched for
the open-chromatin marks H3K4me3, H3K27ac, and H3K56ac
than those showing no EWS-FLI1 binding within 40 kb from the
TSS, but they were more strongly depleted for the repressive-
histone marks H3K27me3 and H3K9me3.
Combining gene expression data with EWS-FLI1 binding, we
observed that proximal and distal binding of EWS-FLI1 were
both associated with higher RNA levels (Figure 2B), suggesting
that EWS-FLI1 acts as a transcriptional activator not only when
it binds in direct vicinity to the TSS but also at enhancers outside
of the promoter region. Proximal binding sites of EWS-FLI1
carried the characteristic histone patterns of promoter regions
(Figure 2C), whereas distal EWS-FLI1 binding sites showed the
chromatin signature of active enhancers with high levels of
H3K27ac and H3K4me1, low levels of H3K4me3, and a dip in
H3K27ac levels at the binding site (Figure 2D). H3K27ac was
consistently associated with EWS-FLI1 binding, both for pro-
moter regions and for distal enhancer elements. To identify
DNA methylation patterns associated with EWS-FLI1 binding,
we thus compared DNA methylation levels of H3K27ac peaks
with and without EWS-FLI1 binding, and we observed signifi-
cantly lower DNA methylation levels among the EWS-FLI1-
bound regions (Figure 2E). This result is consistent with recent
evidence that active transcription factors can reduce DNA
methylation at their binding sites (Stadler et al., 2011).
Collectively, our results support a strong association of EWS-
FLI1 binding with high gene expression, open chromatin, nucle-
osome depletion, and reduced DNAmethylation. These patterns
hold true for both promoters and enhancers and for both prox-
imal and distal binding.We did not observewidespread co-local-
ization of EWS-FLI1 with repressive chromatin, suggesting that
the repressive effect of EWS-FLI1 observed for a sizable fraction
of its target genes (Figures 3A and 3B) is either indirect or caused
by the depletion of active histone marks.
Chromatin-Based Clusters of EWS-FLI1-Dependent
Transcripts
Several studies mapped EWS-FLI1 target genes using expres-
sion microarrays and/or ChIP-seq analysis of EWS-FLI1 binding
(Bilke et al., 2013; Kauer et al., 2009; Prieur et al., 2004; Riggi
et al., 2008; Smith et al., 2006; Tirode et al., 2007). Both
approaches are useful but limited in their insight into the under-
lying regulatory mechanisms. We hypothesized that epigenome
maps could help identify distinct modes of transcriptional regu-
lation, and we devised a bioinformatic approach to classifyors
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Figure 2. Genome-wide Association of Chromatin State with RNA Levels and EWS-FLI1 Binding
(A) Composite plots showing average ChIP-seq and ATAC-seq intensities around the TSS. Gene promoters are stratified in two ways: by RNA levels (top row,
shades of blue) and by their distance to the nearest EWS-FLI1 binding peak (bottom row, shades of red).
(B) Violin plot visualizing the distribution of RNA levels for highly expressed genes (top 20%), moderately expressed genes (20% to 80%), and lowly expressed
genes (bottom 10%) and for genes with EWS-FLI1 binding peaks located in the promoter region (<5 kb from the TSS), distal to the TSS (5–40 kb), or nowhere
nearby (>40 kb). The observed expression differences based on distance to nearest EWS-FLI1 peaks were highly significant (p < 10100, Wilcoxon signed-rank
test).
(C) Composite plots showing the average ChIP-seq and ATAC-seq intensities for EWS-FLI1 binding peaks located proximal to the nearest TSS (<5 kb from the
TSS). All ChIP-seq data are on the same scale, while the ATAC-seq intensities were rescaled to fit the plot.
(D) Composite plots for EWS-FLI1 binding peaks located distal to the nearest TSS (>5 kb from the TSS). The scale is identical to (C).
(E) Histogram showing the distribution of DNA methylation levels in the EWS-FLI1-high state among H3K27ac peaks that are EWS-FLI1 bound (blue) versus not
bound (red). The two distributions are significantly different (p < 1016, Kolmogorov-Smirnov test).
See also Figure S2.genes in a way that takes biological knowledge about chromatin
regulation into account (Figure S3; Supplemental Experimental
Procedures).
First, we identified all genes that were significantly downregu-
lated or upregulated upon EWS-FLI1 knockdown, according to
our RNA-seq data (Figure 3A). To emphasize that the regulatory
relationship with EWS-FLI1 may be direct or indirect, we refer
to these genes as ‘‘EWS-FLI correlated’’ and ‘‘EWS-FLI1 anti-
correlated’’ rather than ‘‘EWS-FLI1 activated’’ and ‘‘EWS-FLI1
repressed.’’ In total, 1,287 transcripts were significantly corre-
lated with EWS-FLI1 (i.e., more highly expressed in the EWS-
FL1-high state than in the EWS-FLI1-low state, which is equiva-
lent to downregulation upon EWS-FLI1 knockdown), and 1,446
transcripts were significantly anticorrelated (i.e., more highly
expressed in the EWS-FLI1-low state, which is equivalent to
upregulation upon EWS-FLI1 knockdown) (Figure 3B).
In a second step, we annotated all correlated and anticorre-
lated transcripts with ChIP-seq intensity levels in their promoter
regions, focusing on the five histone marks that are generally
associated with gene promoters (Figure 3C). We then clustered
the transcripts based on their histone marks in the state where
they are more lowly expressed (correlated transcripts: EWS-Cell RFLI1-low state after EWS-FLI1 knockdown; anticorrelated tran-
scripts: EWS-FLI1-high state before EWS-FLI1 knockdown). To
that end, an initial step of unsupervised clustering was followed
by expert classification of selected transcripts and supervised
prediction of cluster membership for all transcripts (Figure S3).
Cluster 1 comprises transcripts carrying all four active-promoter
marks (H3K4me3, H3K4me1, H3K27ac, and H3K56ac), but not
the repressive H3K27me3 mark; cluster 2 transcripts carry
both H3K4me3 and H3K4me1 but lack the histone-acetylation
marks; cluster 3 transcripts are marked by H3K4me1 only; and
cluster 4 is characterized by the repressive mark H3K27me3 in
the presence or absence of H3K4 methylation. Using a logistic
regressionmodel for predicting cluster membership, most corre-
lated and anticorrelated transcripts (82% and 80%) were placed
unambiguously in one of the four clusters (Figures 3D and 3E).
Examples of EWS-FLI1-anticorrelated transcripts for each of
the four clusters are shown in Figures 3F–3I.
Functional Characteristics and Chromatin Dynamics of
EWS-FLI1-Regulated Transcripts
To validate the biological relevance of our chromatin-based gene
clusters, we analyzed gene set enrichment and overlap of theireports 10, 1082–1095, February 24, 2015 ª2015 The Authors 1085
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promoters with catalogs of regulatory elements. Each cluster
showed specific enrichment patterns, which were similar among
EWS-FLI1-correlated and anticorrelated transcripts. Cluster 1
promoters were highly enriched for polymerase binding and
transcription initiation activity in a broad range of cell types (Fig-
ure 4A), and they were also enriched for CpG islands (Figures 3D
and 3E), which tend to associate with strong and widely active
promoters. Cluster 2 promoters had lower overlap with CpG
islands and a strong association with tissue-specific patterns
of open versus repressed chromatin and with binding of tis-
sue-specific transcription factors. Cluster 3 comprised tissue-
specific genes that lackCpG islands. Finally, cluster 4 transcripts
were strongly enriched for Polycomb repressive complex 2
binding across many cell types.
In addition to the enrichment patterns that were shared
between EWS-FLI1-correlated and anticorrelated clusters, we
also observed interesting differences. For example, EWS-FLI1
promoter binding was more common for EWS-FLI1-correlated
transcripts (i.e., those that are downregulated after knockdown
of EWS-FLI1) than for anticorrelated transcripts (Figures 3D,
3E, and 4A). Furthermore, when comparing each EWS-FLI1-
correlated cluster to the corresponding EWS-FLI1-anticorre-
lated cluster (Figure 4B), we observed a striking enrichment for
binding of E2F transcription factors among the EWS-FLI1-corre-
lated transcripts, reinforcing a previously reported link between
EWS-FLI1 and E2F (Bilke et al., 2013). The EWS-FLI1-correlated
transcripts were also enriched for proliferation gene sets, consis-
tent with the ability of EWS-FLI1 to accelerate cell growth. In
contrast, anticorrelated transcripts were enriched for gene sets
that are characteristic of adult stem cells and for binding of
both components of the AP-1 transcription factor, FOS and JUN.
The chromatin-based gene clusters not only showed distinct
patters of functional enrichment but also responded differently
to EWS-FLI1 knockdown (Figure 4C). Among the EWS-FLI1-
correlated transcripts, H3K27ac was most strongly reduced at
cluster 1 promoters after EWS-FLI1 knockdown, whereas
H3K4me3 and H3K4me1 signals were largely retained even in
the EWS-FLI1-low state. In contrast, clusters 2 and 3 showed
reduced levels for all three marks (H3K4me3, H3K4me1, and
H3K27ac), and cluster 4 promoters underwent relatively minor
changes upon EWS-FLI1 knockdown. The EWS-FLI1-anticorre-
lated clusters showed a more uniform response across clusters
with increases in H3K4me3 and H3K27ac (Figure 4D). Together,
these observations indicate that EWS-FLI1 expression promotes
transcription of its target genes in at least two distinct ways: first,Figure 3. Four Chromatin-Based Clusters of EWS-FLI1-Regulated Gen
(A) Scatterplot comparing RNA levels between the EWS-FLI1-high state (x axis,
(y axis, RNA collected 53 hr after inducing shRNA knockdown). Differentially exp
they belong to (as defined in D and E).
(B) Total number of differentially expressed genes and icons depicting their change
coding is used throughout the figures to indicate which epigenetic and transcriptio
FLI1 levels upon knockdown.
(C) Promoter-associated histone marks that were included in the semi-supervised
this icon are used to depict each of the four chromatin-based gene clusters, with c
the clustered gene promoters.
(D and E) Heatmaps and chromatin-based clustering of EWS-FLI1-anticorrelated
(F–I) Genome browser screenshots with one example gene from each anticorrela
See also Figure S3.
Cell Rby further increasing H3K27ac levels and transcription of genes
that are already widely expressed in proliferating cells (corre-
lated cluster 1); and second, by establishing or maintaining the
chromatin signature of active promoters (H3K4me3, H3K4me1,
and H3K27ac) at cell type specific genes that would otherwise
be silent in these cells (correlated clusters 2 and 3). Furthermore,
the relatively uniform response among the anticorrelated clus-
ters indicates that EWS-FLI1 mediated repression involves
mechanisms that decrease H3K27ac in similar ways across all
four EWS-FLI1 anticorrelated clusters.
Based on these promoter-centric analyses, H3K27ac and, to a
lesser degree, H3K4me3 and H3K4me1 emerged as the histone
marks that were most strongly affected by EWS-FLI1 knock-
down. This result was corroborated bywestern blots for all seven
histonemarks in additional Ewing sarcoma cell lines (TC252, SK-
N-MC, and ST-ET-7.2), where we observed a global reduction in
H3K4me3 and H3K27ac levels upon knockdown of EWS-FLI1
(Figure 4E). These data indicate that the global and EWS-FLI1-
dependent increase of active chromatin may represent a key
mechanism of transcriptional rewiring in Ewing sarcoma cells.
Cluster-Specific Transcriptional Response to
Treatment with Histone Deacetylase Inhibitors
Given that H3K27ac was most variable between the chromatin-
based gene clusters and also most dynamic upon EWS-FLI1
knockdown (Figures 3 and 4), we hypothesized that the clustered
genes should respond differently to induced global changes of
acetylation, which would support the clusters’ usefulness for
identifying distinct modes of gene regulation among EWS-FLI1
target genes. To test this hypothesis, we treated the cells with
histone acetyltransferase (HAT) inhibitors and histone deacety-
lase (HDAC) inhibitors. These experiments were done for both
the EWS-FLI1-high and the EWS-FLI1-low cell state, and they
used drug concentrations that were low enough to avoid broad
toxicity. None of the three HAT inhibitors that we tested (C646,
CPTH2, and anacardic acid) had an effect on cell survival or
gene expression at the chosen concentrations (data not shown);
hence, we focused our analysis primarily on the HDAC inhibitors
(Figures 5 and S4).
HDAC inhibitors are being evaluated as drug candidates for
Ewing sarcoma (Arnaldez and Helman, 2014), but here we
used them solely as a chemical biology tool for validating
our gene clustering, and at much lower concentrations than if
our goal were to selectively kill EWS-FLI1-expressing cells. For
two out of three HDAC inhibitors tested—namely, romidepsines
RNA collected prior to knockdown of EWS-FLI1) and the EWS-FLI1-low state
ressed genes are indicated by triangles colored according to the gene cluster
as EWS-FLI1 correlated (red) or EWS-FLI1 anticorrelated (blue). This graphical
nal changes move in the same or the opposite direction compared to the EWS-
clustering of EWS-FLI1-correlated and anticorrelated transcripts. Variations of
olored fields indicating the presence of the corresponding histone mark among
genes (D) and EWS-FLI-correlated genes (E).
ted cluster. Histone data are shown for the EWS-FLI1-high state.
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Figure 4. Functional Enrichment and Changes in Histone Marks among Chromatin-Based Gene Clusters
(A) Summary statistics and functional enrichment analysis for the chromatin-based gene clusters (see Figure 3B and 3C for an explanation of the colored icons).
The enrichment column summarizes the most significant terms when comparing each cluster to all other clusters (see http://tomazou2015.
computational-epigenetics.org for tables with all enriched terms).
(B) Functional enrichment analysis of correlated versus anticorrelated genes within each cluster. The enrichment columns summarize the most significant terms
when comparing each cluster of EWS-FLI1-correlated genes to the corresponding cluster of EWS-FLI1-anticorrelated genes.
(C and D) Bar charts summarizing the changes in histone marks at promoters of correlated (C) and anticorrelated (D) genes in response to EWS-FLI1 knockdown.
The scale of the x axis is the same across clusters and panels, and it indicates relative increase (+) or decrease () of the ChIP-seq signal intensity after EWS-FLI1
knockdown.
(E) Western blots showing global levels of EWS-FLI1 and of seven histone marks for the EWS-FLI1-high and EWS-FLI1-low states. Actin and Ponceau S staining
were used as loading controls for EWS-FLI1 and histone marks, respectively. Data are shown for the inducible knockdown cell line (A673) and for three additional
Ewing sarcoma cell lines (TC252, SK-N-MC, and STA-ET-7.2). Boxes highlight H3K27ac and H3K4me3 as the two histone marks whose global levels correlate
with EWS-FLI1 expression in all four Ewing sarcoma cell lines. All western blots were done in multiple biological replicates, and this panel combines repre-
sentative blots from these experiments.(FK-228) and entinostat (MS-275), but not Vorinostat (SAHA)—
we were able to identify concentrations that fulfilled all three
criteria that were crucial for our experiment: (1) no effect on
cell viability (Figures 5A and S4A), (2) global increase in histone
acetylation levels (Figure 5B), and (3) no effect on EWS-FLI1
expression levels as a potential confounder (Figure 5B).
We performed RNA-seq to measure the transcriptome
response to each HDAC inhibitor at the chosen concentrations
(Figures 5C–5E, S4B, and S4C). Both romidepsin and entinostat1088 Cell Reports 10, 1082–1095, February 24, 2015 ª2015 The Authspecifically upregulated the expression of EWS-FLI1-anticorre-
lated transcripts in cells with high EWS-FLI1 levels, suggesting
that the (direct or indirect) repressive effect of EWS-FLI1 is
partially reversed by treating EWS-FLI1-high cells with HDAC
inhibitors. Among the anticorrelated transcripts, cluster 1 was
least affected by treatment with HDAC inhibitors, most likely
because cluster 1 promoters already carried high levels of
H3K27ac and may therefore be less sensitive to HDAC inhibition
(Figures 5D and S4C). In contrast, clusters 2, 3, and 4 carried lowors
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levels of H3K27ac in the EWS-FLI1-high state and responded
more strongly to treatment with HDAC inhibitors. Examples for
each of the four clusters are shown in Figure 5F.
Among the EWS-FLI1-correlated genes, there was no global
trend in either direction (Figure 5C), but we observed strong clus-
ter-specific differences in the EWS-FLI1-low state (Figures 5E
and S4B). Clusters 2 and 4 were consistently upregulated
in response to HDAC inhibition, whereas no such trend was
observed for cluster 3, and cluster 1 genes were even slightly
downregulated. Specific examples are shown in Figure 5G.
These results indicate that EWS-FLI1 activates certain genes in
cluster 2 and 4 by interfering with HDAC function, and treatment
with HDAC inhibitors appears to recapitulate this effect in EWS-
FLI1-low cells.
Widespread Reprogramming of Enhancers and
Super-Enhancers by EWS-FLI1
Our promoter-centric analysis (Figures 3 and 4) established
H3K4me3 and H3K27ac as the two histone marks that
were most strongly associated with EWS-FLI1 expression.
H3K4me3 is a prototypic promoter mark, and the observed
changes in H3K4me3 were indeed located almost exclusively
in promoter regions. By contrast, not only does H3K27ac occur
in promoter regions (where it tends to overlap with H3K4me3),
but it is also a defining mark of active enhancers when occurring
in the absence of H3K4me3 (Creyghton et al., 2010; Rada-
Iglesias et al., 2011). We therefore investigated the effect of
EWS-FLI1 expression on H3K27ac beyond gene promoters,
comparing H3K27ac patterns before and after knockdown of
EWS-FLI1 across the genome. In total, 15,300 H3K27ac peaks
showed significantly lower intensity in EWS-FLI1-low cells
(‘‘EWS-FLI1 correlated peaks’’), and 18,727 H3K27ac peaks
showed significantly higher intensity (‘‘EWS-FLI1 anticorrelated
peaks’’). 27% of correlated peaks and only 6% of anticorrelated
peaks overlapped with promoter regions (Figures 6A and S5A),
indicating that the majority of EWS-FLI1-associated H3K27ac
peaks are located at enhancer elements outside of promoter
regions.
We observed striking differences between EWS-FLI1-
correlated and anticorrelated H3K27ac peaks, which became
apparent when we stratified all peaks by the strength of
H3K27ac signal difference upon EWS-FLI1 knockdown. Among
EWS-FLI1-correlated enhancers, only 10% of the top 20%mostFigure 5. Transcriptome Response upon Treatment with Histone Deac
(A) Dose-response curves showing cell viability for three histone deacetylase (H
shown for the EWS-FLI1-high state. Error bars represent the SEM of triplicate e
selected for measuring the transcriptome response.
(B)Western blots showing the effect of three HDAC inhibitors on the global levels o
and the EWS-FLI1-low state (right). Treatment with 0.1%DMSOwas used as nega
loading controls for the western blot. All western blots were done in several biolo
(C) Violin plots visualizing gene expression changes in response to treatment with
untreated samples (y axis) is shown for EWS-FLI1-correlated genes (red), EWS-
EWS-FLI1-high state (left) and for the EWS-FLI1-low state (right). All values are m
(D and E) Violin plots visualizing gene expression changes for each of the four c
genes in the EWS-FLI1-high state (D) and on EWS-FLI-correlated genes in the E
(F and G) Genome browser screenshots illustrating the RNA-seq response to
Anticorrelated genes are shown in the EWS-FLI1-high state (F), and correlated g
See also Figure S4.
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62% of the bottom 20% peaks (which are still significantly
different for H3K27ac between the EWS-FLI1-high and low
states) were located in promoters (Figure 6B). No such differ-
ences were observed for EWS-FLI1-anticorrelated peaks, of
which 5% and 7%were located in promoters. We also identified
strong differences in EWS-FLI1 binding, with 77%of the top hun-
dred EWS-FLI1-correlated H3K27ac peaks being EWS-FLI
bound, while the percentage for EWS-FLI1 binding fell to 20%
when calculated across all EWS-FLI1-correlated peaks and to
only 1% for EWS-FLI1-anticorrelated peaks (Figure 6C). Finally,
for the other histone marks tested we observed much lower
overlap of EWS-FLI1 (Figure S5B), indicating that EWS-FLI1 pri-
marily drives H3K27ac at selected promoters and enhancers
throughout the genome.
Our observation that the strongest EWS-FLI1-correlated en-
hancers were qualitatively different from other H3K27ac peaks
is reminiscent of super-enhancers (Hnisz et al., 2013; Love´n
et al., 2013; Whyte et al., 2013). We therefore investigated
whether super-enhancers occur in EWS-FLI1 expressing cells
and how they might respond to EWS-FLI1 knockdown. Using a
published method for H3K27ac-based annotation of super-en-
hancers (Love´n et al., 2013; Whyte et al., 2013), we identified
697 super-enhancers in the EWS-FLI1-high state and anno-
tated them with their neighboring genes (http://tomazou2015.
computational-epigenetics.org). Overall, more than 10% of
H3K27ac peaks in EWS-FLI1-high cells were located in super-
enhancers (Figure S5C), and super-enhancers had much higher
cumulative H3K27ac enrichment than typical enhancers (Fig-
ure 6D). This strong enrichment of H3K27ac was largely due to
the exceeding length of super-enhancers (median length of
27,818 base pairs as compared to 1,196 base pairs for typical
enhancers; Figure S5D) and not due to higher H3K27ac signal in-
tensity per base pair (Figure S5E). As illustrated in Figure 6E,
super-enhancers were essentially agglomerates of co-located
H3K27ac peaks over a range of several dozen kilobases, while
typical enhancers rarely comprised more than two H3K27ac
peaks and were typically shorter than 2 kb. Several of the top su-
per-enhancers were located near genes with known roles in cell
proliferation, differentiation, and apoptosis. We also observed
widespread loss of H3K27ac upon knockdown of EWS-FLI1
for some super-enhancers (Figure 6E), while others displayed
more localized changes affecting only those H3K27ac peaksetylase Inhibitors
DAC) inhibitors at different concentrations and different time points. Data are
xperiments, and red squares indicate well-tolerated concentrations that were
f histone acetylation and EWS-FLI1 expression in the EWS-FLI1-high state (left)
tive control for treatment effect, whereas actin and Ponceau Swere included as
gical replicates.
sublethal doses of two HDAC inhibitors. Log fold change between treated and
FLI1-anticorrelated genes (blue) and all other genes (gray), separately for the
eans across two biological replicates.
hromatin-based gene clusters (Figure 3), focusing on EWS-FLI-anticorrelated
WS-FLI1-low state (E).
romidepsin treatment. One example gene is shown for each gene cluster.
enes are shown in the EWS-FLI1-low state (G).
ors
AD
F G
B
E
C
(EWS-FLI1 High State)
Figure 6. Characteristic H3K27ac Patterns and Widespread Enhancer Reprogramming in EWS-FLI1-Dependent Cells
(A) Differences in genomic localization between differential H3K27ac peaks that are correlated (higher intensity in the EWS-FLI1-high state) or anticorrelated
(higher intensity in the EWS-FLI1-low state) with EWS-FLI1 levels.
(B) Bar charts showing the proportion of differential H3K27ac peaks that overlap with gene promoters (2-kb regions upstream of the TSS), ranked and binned by
the magnitude of change in H3K27ac signal intensity upon EWS-FLI1 knockdown.
(C) Line chart showing the proportion of differential H3K27ac peaks that overlap with EWS-FLI1 binding sites, ranked by magnitude of the change in H3K27ac
signal intensity upon EWS-FLI1 knockdown. The percentages (y axis) refer to the top-N peaks up to the indicated rank (x axis).
(D) Line chart illustrating the strong enrichment of H3K27ac intensity at 697 super-enhancers (highlighted in red). Super-enhancers were annotated with ROSE
(Love´n et al., 2013; Whyte et al., 2013).
(E) Genome browser screenshots showing examples of a typical enhancer (top) and a super-enhancer (bottom). These enhancer and super-enhancer elements
(gray bars) are cell-type specific when compared to multi-tissue H3K27ac data from the ENCODE project (bottom track).
(legend continued on next page)
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that overlapped with EWS-FLI1 binding sites (Figure S5F). Inter-
estingly, EWS-FLI1 binding sites and EWS-FLI1-correlated
H3K27ac peaks were both more likely than other H3K27ac
peaks to be located in super-enhancers (Figure S5G); in addition,
more than half of the super-enhancers in EWS-FLI1-expressing
cells contained at least one EWS-FLI1 binding event, and a
similar fraction contained at least one EWS-FLI1-correlated
H3K27ac peak (Figure S5H).
To assess the cell-type specificity of EWS-FLI1-correlated
H3K27ac peaks, we studied their association with active regula-
tory elements in 72 human cell types, based onDNase hypersen-
sitivity data (Sheffield et al., 2013). Our analysis uncovered
a striking trend toward high cell-type specificity among the
strongest EWS-FLI1-correlated, EWS-FLI1-bound, and super-
enhancer-associated H3K27ac peaks (Figure 6F). This trend
was already visible for H3K27ac peaks in promoters and in
typical enhancers, but the association with super-enhancers
and overlap with EWS-FLI1 binding sites further increased the
cell-type specificity (Figure 6G). Most notably, 37% of the
2,322 strongest EWS-FLI1-correlated H3K27ac enhancer peaks
overlapped with DNase-hypersensitive sites present only in the
one EWS-FLI1 expressing cell line that was part of the DNase
dataset (SK-N-MC) and were thus unique to Ewing sarcoma.
In summary, these results provide strong evidence that EWS-
FLI1 not only regulates genes and promoters but also estab-
lishes highly cell-type-specific enhancers and super-enhancers
in EWS-FLI1-expressing cells.
DISCUSSION
Global Epigenome Dynamics in EWS-FLI1-Dependent
Cells
In this study, we used a Ewing sarcoma cell line with tunable
EWS-FLI1 expression to uncover connections between this
oncogenic fusion protein and the epigenome. Based on both
ChIP-seq and western blots, H3K27ac emerged as the mark
that was most strongly affected by EWS-FLI1 knockdown.
33,170 H3K27ac peaks were significantly altered throughout
the genome (Figure 7A), and 80% of the most strongly EWS-
FLI1-correlated H3K27ac peaks were bound by EWS-FLI1 (Fig-
ure 6C). In contrast, H3K27ac levels in regions that were not
bound by EWS-FLI1 were either correlated or anticorrelated
with EWS-FLI1 expression and likely driven by indirect mecha-
nisms of transcription regulation. Similar but weaker patterns
of EWS-FLI1 association were also observed for H3K4me3 and
H3K4me1 (Figure 7A), while the other studied histone marks
did not show widespread changes upon EWS-FLI1 knockdown.
Differences in response to EWS-FLI1 knockdown were also
notably absent for DNA methylation (Figure 7B). Although this
mark was anticorrelated with EWS-FLI1 binding (Figure 2E), no(F) Bar plots showing the degree to which differential H3K27ac peaks co-localiz
DNase-hypersensitivity data for 72 cell types was used to quantify cell type specifi
chromatin, whereas low values indicate enhancers that are highly tissue speci
magnitude of change in signal intensity upon EWS-FLI1 knockdown (x axis).
(G) Q-Q plots showing the difference in tissue specificity for all EWS-FLI1-correl
EWS-FLI1 peaks (bottom).
See also Figure S5.
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knockdown—at a time point that should be sufficient for de novo
methylation to have at least started. Hence, it seems possible
that Ewing sarcoma cells retain an epigenetic memory of prior
EWS-FLI1 binding as part of their DNA methylation patterns.
Promoter Regulation by EWS-FLI1
Chromatin-based promoter analysis identified four clusters
of EWS-FLI1-correlated transcripts and four clusters of EWS-
FLI1-anticorrelated transcripts. These clusters define three
different regulatory modes (Figure 4). First, EWS-FLI1-correlated
cluster 1 genes, such as the cell-cycle regulator and proto-onco-
gene CCND1 (Sanchez et al., 2008), were expressed even in the
EWS-FLI1-low state and carried all histone marks of active pro-
moters, but their H3K27ac and transcription levels were higher
in the EWS-FLI1-high state (Figure 7C). Many of the correlated
cluster 1 genes were associated with cell proliferation, suggest-
ing that increased H3K27ac at widely expressed genes may
drive the rapid proliferation of EWS-FLI1-expressing cells. Sec-
ond, the genes in EWS-FLI1-correlated clusters 2 and 3 (Fig-
ure 4A) weremore tissue specific than genes in correlated cluster
1, and they lacked active promoter marks such as H3K27ac and/
or H3K4me3 in the EWS-FLI1-low state. EWS-FLI1-dependent
establishment of the missing histone marks may aberrantly
activate these genes, as illustrated by the hematopoietic proto-
oncogene MYB that was specifically expressed in the EWS-
FLI1-high state (Figure 7D). Third, EWS-FLI1-anticorrelated
genes had higher H3K27ac levels in the EWS-FLI1-low state in-
dependent of their cluster association and H3K27ac level in the
EWS-FLI-high state (Figure 4D), which is illustrated by the AP-1
component FOSL1 (Figure 7E). Intriguingly, we observed broad
enrichment for AP-1 binding in other cell types among EWS-
FLI1-anticorrelated gene promoters (Figure 4B), suggesting
that EWS-FLI1 may repress a sizable fraction of its target genes
by interfering with the activating role of AP-1. HDACs seem to
play a role in the process, given the upregulation of EWS-FLI1-
anticorrelated genes (clusters 2, 3, and 4) upon treatment
with HDAC inhibitors specifically in the EWS-FLI1-high state
(Figure 5D).
Enhancer and Super-Enhancer Regulation by EWS-FLI1
Our analysis of H3K27ac resulted in a genome-wide catalog of
EWS-FLI1-associated enhancers and super-enhancers. Strik-
ingly, the most dynamic enhancers upon EWS-FLI1 knockdown
were also the most cell-type specific (Figure 6), which is
illustrated by the absence of any ENCODE signal for H3K27ac
at the EWS-FLI1-bound enhancers upstream of the CCND1
promoter (Figure 7C). A large percentage of the observed
EWS-FLI1-correlated H3K27ac peaks overlapped exclusively
with regulatory elements in SK-N-MC cells, which is the onee with open chromatin regions in other cell types. An ENCODE dataset with
city (y axis). High values indicate regions with widespread or ubiquitously open
fic. The differential H3K27ac peaks are ranked and binned according to the
ated enhancers versus those in super-enhancers (top) and those overlapping
ors
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Figure 7. Epigenome Dynamics and Modes
of Transcriptional Regulation in EWS-FLI1-
Dependent Cells
(A) Violin plots showing the distribution of fold
change upon EWS-FLI1 knockdown for the three
most strongly EWS-FLI1-correlated histone marks
(H3K4me3, H3K4me1, and H3K27ac). Data are
shown separately for peaks that are bound or not
bound by EWS-FLI1, and the difference between
the two distributions is highly significant for all
three histone marks (p < 1016, Kolmogorov-
Smirnov test).
(B) Violin plots showing the distribution of differ-
ential DNA methylation at H3K27ac peaks that are
bound or not bound by EWS-FLI1. The difference
between the two distributions is not significant
(p > 0.05, Kolmogorov-Smirnov test).
(C) Genome browser screenshot showing CCND1,
an EWS-FLI1-correlated cluster 1 gene with an
established role in cell proliferation. Yellow boxes
indicate EWS-FLI1-correlated H3K27ac peaks at
EWS-FLI1-bound enhancers, which are highly
cell-type specific relative to the ENCODE
H3K27ac track. Black boxes highlight H3K27ac
peaks associated with EWS-FLI1 binding in the
promoter region, which are not cell-type specific.
(D) Genome browser screenshot showing MYB,
an EWS-FLI1-correlated cluster 2 gene that is a
known proto-oncogene of the hematopoietic
lineage. The H3K27ac peak in the promoter region
(yellow box) is EWS-FLI1 correlated and lost
after knockdown, but it is not directly bound by
EWS-FLI1.
(E) Genome browser screenshot showing FOSL1,
an EWS-FLI1-anticorrelated cluster 1 gene that
encodes a component of the AP-1 transcription
factor. The yellow box indicates EWS-FLI1-anti-
correlated H3K27ac peaks at a constitutive
enhancer element, while the promoter has active
histone marks even in the EWS-FLI1-high state.
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EWS-FLI1-expressing cell line in a published catalog with DNase
hypersensitivity data for 72 human cell types (p < 10100, Fisher’s
exact test). EWS-FLI1 also appears to contribute to cell-type-
specific enhancer signatures by converting broadly active en-
hancers to a poised state, as illustrated by the enhancer element
upstream of the FOSL1 locus (Figure 7E). While our study was in
revision, Riggi et al. published conclusive evidence that EWS-
FLI1 binds cis-regulating elements shared by Ewing sarcoma
cell lines and primary tumors (Riggi et al., 2014), suggesting
that our observations are not only limited to cell lines but also
relevant for Ewing sarcoma biology in patients.
In summary, the establishment and analysis of reference epige-
nomes forEWS-FLI1-highandEWS-FLI1-lowcellsnotonlyconsti-
tutes a first comprehensive epigenome dataset for a solid cancer
that is driven by an oncogenic fusion protein, but it also provides
relevant insights into themechanismsbywhicha singleoncogenic
event has shaped a conductive epigenome. The dataset is
available for interactive exploration and data download (http://
tomazou2015.computational-epigenetics.org), thus providing a
genome-wide reference that can guide future work on regulatory
mechanisms and epigenetic drug effects in Ewing sarcoma.
EXPERIMENTAL PROCEDURES
For full details, see the Supplemental Experimental Procedures.
Epigenome Mapping
A673 cells were cultured as previously described (Carrillo et al., 2007). DNA,
chromatin, RNA, and protein were collected following standard procedures
from untreated cells (EWS-FLI1-high state) and 53 hr after adding doxycycline
to the media (EWS-FLI1-low state). To assess DNA methylation, WGBS and
RRBS experiments were performed using custom protocols (see the Supple-
mental Experimental Procedures for details), and the data of both assays were
merged. ChIP-seq experiments were performed using the iDeal ChIP-seq
kit (Diagenode) according to manufacturer instructions. ATAC-seq was
performed as previously described (Buenrostro et al., 2013) with minor adap-
tations for A673 cells. RNA-seq used Illumina kits for strand-specific library
preparation. All sequencing was performed by the Biomedical Sequencing
Facility at CeMM using Illumina HiSeq 2000 sequencers.
The epigenome maps as well as the raw and processed data underlying
the presented analyses are available online at http://tomazou2015.
computational-epigenetics.org.
Epigenetic Gene Clustering
We clustered all EWS-FLI1-associated genes based on the ChIP-seq signal
intensity of five promoter-associated histone marks in the vicinity of the TSS
(excluding H3K36me3 and H3K9me3, which were rarely present in promoter
regions), using a two-step semi-supervised clustering method. Multinomial
logistic regression models were trained based on expert-curated examples
and used to classify EWS-FLI1-regulated genes derived from the RNA-seq
data. We trained separate classifiers for identifying clusters among the
EWS-FLI1-correlated genes and among the EWS-FLI1-anticorrelated genes.
Enrichment Analysis
To functionally annotate the gene clusters, we identified significant overlap be-
tween gene sets derived from our dataset and gene sets obtained from several
public databases (see the Supplemental Experimental Procedures for details).
In addition to gene-based enrichments, we also developed a method for
region-based enrichment analysis called location overlap analysis (LOLA;
http://lola.computational-epigenetics.org), and we identified sets of functional
elements that significantly co-localized with the promoters of a given gene
cluster. We used Fisher’s exact test to establish significance, and odds ratios
as well as p values were used to rank the results. Comparisons were done (1)1094 Cell Reports 10, 1082–1095, February 24, 2015 ª2015 The Authagainst the background of all genes identified by our RNA-seq analysis to iden-
tify enrichment patterns among EWS-FLI1-regulated genes, (2) against the
background of genes in other clusters to identify cluster-specific enrichment
patterns separately for EWS-FLI1-correlated and EWS-FLI1-anticorrelated
genes, and (3) against the background of genes in the same cluster but with
opposite direction of EWS-FLI1 regulation (correlated or anticorrelated) to
identify upregulation- versus downregulation-specific enrichment patterns
separately for each cluster.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.01.042.
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